Halozyme Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HALO research report →
Range $90 – $130
Price Chart
About the company
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
- CEO
- Helen I. Torley
- IPO
- 2004
- Employees
- 423
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on HALO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.41B
- P/E
- 22.15
- Fwd P/E
- 10.55
- PEG
- -1.57
- P/S
- 5.89
- P/B
- -191.67
- EV/EBITDA
- 15.92
- Div Yield
- 0.00%
- Gross Margin
- 82.27%
- Op Margin
- 55.91%
- Net Margin
- 26.93%
- ROE
- 544.26%
- ROIC
- 22.61%
Latest fiscal year · YoY change
- Revenue
- $1.40B+37.6%
- Gross Profit
- $1.17B+36.4%
- Op Income
- $802.59M
- Net Income
- $316.89M-28.6%
- EPS
- $2.64-24.6%
- OCF Growth
- +36.0%
- FCF Growth
- +37.6%
- 52W High
- $134.00
- 52W Low
- $61.23
- 50D MA
- $113.53
- 200D MA
- $85.83
- Beta
- 0.90
- RSI (14)
- 21
- Avg Volume
- 2.27M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Halozyme delivered a record quarter with strong royalty growth, higher guidance, and continued pipeline expansion across ENHANZE, Hypercon, and Aerocon.· November 5, 2026
- Total revenue rose 39% year over year to $493 million, led by record royalty revenue of $341 million, up 44%.
- Adjusted EBITDA reached $336 million with a 68% margin, and non-GAAP diluted EPS was $2.39.
- Management raised full-year 2026 guidance for revenue, royalties, adjusted EBITDA, and EPS.
- New and expanded partner programs added 4 target nominations and kept Halozyme on track for 13 ENHANZE clinical programs by year-end.
- The company said recent European court rulings strengthened its IP position versus Merck’s subcutaneous Keytruda launch in Europe.
Halozyme reported third-quarter total revenue of $493 million, up 39% from $354.3 million a year ago. Royalty revenue was a record $341 million, up 44%; DARZALEX royalty revenue was $153.5 million, VYVGART royalties were $88.1 million, and Phesgo royalty revenue was $34.3 million. Net income increased 41% to $247 million, adjusted EBITDA increased 35% to $336.2 million, GAAP diluted EPS was $2.01, and non-GAAP diluted EPS was $2.39. For the full year 2026, Halozyme now expects total revenue of $1.86 billion to $1.925 billion, royalty revenue of $1.235 billion to $1.255 billion, product sales of $525 million to $540 million, adjusted EBITDA of $1.24 billion to $1.29 billion, and non-GAAP diluted EPS of $8.75 to $9.05; adjusted EBITDA margin is still expected at approximately 67%.
Helen Torley framed the quarter as another exceptionally strong one, emphasizing the breadth and durability of the ENHANZE platform and the record revenue performance it is producing. She highlighted multiple commercial wins, new partner nominations, and continued advancement of Hypercon and Aerocon, describing them as additional compounding platforms layered on top of ENHANZE. Her tone was confident and constructive, with a clear focus on long-term expansion rather than just near-term results.
Darren Snellgrove emphasized that the quarter reflected continued royalty diversification, operating leverage, and strong cash generation. He noted $1.08 billion in cash, cash equivalents and marketable securities, $3.3 billion of long-term debt, and net leverage of 2.4x, while also pointing to $400 million of share repurchases in 2026 and the recently completed $1.5 billion convertible note offering. On the cost side, R&D was $27.8 million and SG&A was $58.2 million, with higher SG&A driven mainly by consulting fees including Merck litigation costs.
Analysts focused on Hypercon commercialization timing, proof-of-concept standards, scale-up risk, and how much value the new platform could contribute. Management said first clinical supplies for two Hypercon partners are expected in the first quarter of 2027 to support Phase I starts in the first half of 2027, and that scale-up is progressing well. On Merck, Halozyme said it has not had conversations with Merck, believes the Dutch ruling blocks key European supply and launch activities, and remains confident it will ultimately prevail in the U.S. appeal process, though that could take until 2028.
The bull case from this call is that Halozyme is still seeing strong growth from its core royalty base while adding new drivers through newer launches and fresh partner nominations. Management also pointed to a deepening pipeline, with 12 ENHANZE programs in clinical development and 13 expected by year-end, plus Hypercon and Aerocon as future royalty engines.
The main risks discussed were litigation and execution: Merck remains a major legal overhang, especially in the U.S., where Halozyme has had adverse rulings so far and expects appeals to run into 2028. Hypercon is still preclinical-to-early clinical, so its revenue contribution is not immediate, and management acknowledged the need to keep advancing scale-up and supply before broader commercialization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.9%
- Shares Outstanding
- 114.01M
- Float Shares
- 112.70M
of shares held by institutions
693 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HALO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Sep 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 9, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Mar 24, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 9, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 6, 22 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Oct 22, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 19, 20 | Filing → |
| Mark WarnerSenate · VA | Sell | Nov 6, 17 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 13.67M | ▲ 397.47K |
| Vanguard Group Inc | 11.57M | ▼ 62.89K |
| Vanguard Capital Management LLC | 5.11M | ▼ 244.86K |
| State Street Corp | 5.06M | ▼ 115.86K |
| Vanguard Portfolio Management LLC | 4.99M | ▼ 312.05K |
| Invesco Ltd. | 3.53M | ▲ 356.22K |
| Two Sigma Investments, LP | 3.52M | ▲ 1.87M |
| D. E. Shaw & Co., Inc. | 3.37M | ▲ 1.37M |
| Morgan Stanley | 2.85M | ▲ 18.12K |
| Boston Partners | 2.76M | ▼ 9.73K |
| Geode Capital Management, LLC | 2.41M | ▼ 105.52K |
| Bank Of America Corp | 2.37M | ▼ 367.32K |
Held by 671 ETFs
Biggest fund positions in HALO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Posard Matthew L. | sell | 3,400 |
| Nov 18, 26 | Posard Matthew L. | sell | 1,600 |
| Nov 16, 26 | Torley Helen | other | 20,000 |
| Nov 12, 26 | Torley Helen | other | 20,000 |
| Nov 16, 26 | Torley Helen | sell | 7,283 |
| Nov 13, 26 | Torley Helen | sell | 7,992 |
| Nov 12, 26 | Torley Helen | sell | 10,711 |
| Nov 16, 26 | Torley Helen | sell | 4,802 |
| Nov 16, 26 | Torley Helen | sell | 1,586 |
| Nov 13, 26 | Torley Helen | other | 1,552 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HALO coverage
Recent articles, reports, and earnings notes.
No research on HALO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HALO report →HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
zacks.com · Nov 20
Halozyme Therapeutics: 3 Technologies, Multiple Big Pharma Partnerships
seekingalpha.com · Nov 19
Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure
benzinga.com · Nov 19
Halozyme Provides Update on German Preliminary Injunction Hearing
prnewswire.com · Nov 19
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,967,600.00 in Stock
defenseworld.net · Nov 19
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,007,600.00 in Stock
defenseworld.net · Nov 19
HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?
zacks.com · Nov 17
Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
fool.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.